Incidence and Clearance of Anal Human Papillomavirus Infection in 16 164 Individuals, According to Human Immunodeficiency Virus Status, Sex, and Male Sexuality: An International Pooled Analysis of 34 Longitudinal Studies
Feixue Wei,Marc T Goodman,Ningshao Xia,Jun Zhang,Anna R Giuliano,Gypsyamber D'Souza,Nancy A Hessol,Maarten F Schim van der Loeff,Jianghong Dai,Karin Neukam,Alexandra de Pokomandy,I Mary Poynten,Ronald B Geskus,Joaquin Burgos,Isabelle Etienney,Anna-Barbara Moscicki,Maria Gabriella Donà,Maura L Gillison,Alan G Nyitray,Rebecca G Nowak,Evy Yunihastuti,Huachun Zou,Carmen Hidalgo-Tenorio,Nittaya Phanuphak,Jean-Michel Molina,Alice M Schofield,Stephen Kerr,Song Fan,Yong Lu,Jason J Ong,Admire T Chikandiwa,Sirinya Teeraananchai,Nicola Squillace,Dorothy J Wiley,Joel M Palefsky,Damien Georges,Catharina J Alberts,Gary M Clifford
DOI: https://doi.org/10.1093/cid/ciac581
2023-02-08
Abstract:Background: Understanding the natural history of anal high-risk human papillomavirus (hrHPV) infection is key for designing anal cancer prevention programs but has not been systematically characterized. Methods: We reanalyzed data from 34 studies including 16 164 individuals in 6 risk groups defined by human immunodeficiency virus (HIV) status, sex, and male sexuality: men who have sex with men (MSM) and people with HIV (MSMWH), HIV-negative MSM, women with HIV (WWH), HIV-negative women, men who have sex with women (MSW) with HIV (MSWWH), and HIV-negative MSW. We used Markov models to estimate incidence and clearance of 13 hrHPV types and their determinants. Results: Human papillomavirus (HPV) 16 had the highest incidence-clearance ratio of the hrHPV types. MSMWH had the highest hrHPV incidence (eg, 15.5% newly HPV-16 infected within 2 years), followed by HIV-negative MSM (7.5%), WWH (6.6%), HIV-negative women (2.9%), MSWWH (1.7%), and HIV-negative MSW (0.7%). Determinants of HPV-16 incidence included HIV status and number of sexual partners for MSM, women, and MSW, and anal sex behavior for MSM only. HPV-16 clearance was lower for people with HIV (PWH) and lower for prevalent than incident infection. Among MSM, increasing age was associated with lower clearance of prevalent, but not incident, HPV-16 infection. Conclusions: This robust and unifying analysis of anal hrHPV natural history is essential to designing and predicting the impact of HPV vaccination and HPV-based screening programs on anal cancer prevention, particularly in MSM and PWH. Importantly, it demonstrates the higher carcinogenic potential of longstanding anal prevalent hrHPV infection than more recent incident infection.